Momenta gets orphan designation for potential pancreatic cancer drug

The fortunes of Momenta Pharmaceuticals for the past few years have been tied up in the company’s attempts to launch generic versions of already-approved drugs...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.